STEMTECH CORPORATION (OTC:GNTW) ANNOUNCES APPOINTMENT OF SANDRA KAZICKAITE TO THE ROLE OF VICE PRESIDENT OF GLOBAL PERFORMANCE
Stemtech Corporation (OTC:GNTW) announced the appointment of Sandra Kazickaite as Vice President of Global Performance, effective November 1, 2021. Kazickaite, who has been with the company since 2007, will oversee IT activities, monitor Key Performance Indicators, and manage corporate projects. Her experience spans multiple departments, enhancing her ability to contribute effectively. President John W. Meyer praised her analytical skills and dedicated contribution to the company's growth and future international expansion.
- Sandra Kazickaite's promotion could bring fresh perspectives to the leadership team.
- Kazickaite's extensive experience within Stemtech may enhance operational efficiency.
- The transition may create uncertainties regarding continuity in leadership during the adjustment period.
MIRAMAR, Fla., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTC:GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has appointed Sandra Kazickaite to the position of Vice President of Global Performance.
Ms. Kazickaite joined Stemtech in 2007. Her responsibilities now include directing Stemtech’s Information Technology activities as well as monitoring Key Performance Indicators and corporate project management, reporting to President and COO John W. Meyer.
She brings a valued and necessary skillset in Project Management, having earned her MBA in the field. Over the last fourteen years with Stemtech, Sandra has had management positions in many of our departments, including marketing and systems, business development, and brings a wealth of knowledge to her newly created role.
“We are proud to promote Sandra to the position of Vice President of Global Performance,” said President and COO John W. Meyer. “Sandra has a keen analytic mind and will be a key factor in coordinating businesses in our existing markets of the U.S., Mexico, Canada, Ecuador, Taiwan, Malaysia, New Zealand, Australia, South Africa and other licensed countries and future international expansion. At Stemtech, we believe in promoting from within, and Sandra has proven her merit throughout her years at the company. It is a pleasure to work with Sandra, and we believe that her dedication and positive contribution to the company will accelerate benefits to be realized by all at Stemtech.”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13th , 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena, 908-675-0581, fpena@stemtech.com
Attachment
FAQ
Who has been appointed as Vice President of Global Performance at Stemtech?
What are Sandra Kazickaite's responsibilities at Stemtech?
When was the announcement of Sandra Kazickaite's appointment made?
How long has Sandra Kazickaite been with Stemtech?
What is the stock symbol for Stemtech Corporation?
